Divergent trial results on cancer vaccines spark questions in the biotech field
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Following a late-stage clinical trial where Merck and Moderna reported their mRNA vaccine, named intismeran autogene, successfully delayed the return and spread of melanoma, researchers are debating whether mRNA technology can be successfully applied to other cancers. Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy founded by Sean Parker, noted the field had eagerly awaited the results, which suggest messenger RNA can train the immune system to target cancer cells.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu